High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes
Peter A. McSweeney(Mesoblast (United States)), Daniel E. Furst(University of California, Los Angeles), John A. Rambharose(Duke University), Keith M. Sullivan(Duke Medical Center), Roger Dansey(Memorial Sloan Kettering Cancer Center), Mark H. Wener(University of Washington), Richard A. Nash(Colorado Blood Cancer Institute), Leslie J. Crofford(Vanderbilt University Medical Center), Jan Storek(University of Washington), Rainer Storb(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Katherine A. Ryan(Duke University), Chen‐Li Cheng(Shanxi University), Leona Holmberg(University of Washington), Ken Russell(Duke University), J. Lee Nelson(University of Washington), Kevin T. McDonagh(University of Michigan), Julie Sunderhaus(City Of Hope National Medical Center), Theodore A. Gooley(Leipzig University), Maureen D. Mayes(The University of Texas Health Science Center)
Cited by 187
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
|Arthritis & Rheumatology|2015|2.8k
Chronic graft-versus-host syndrome in man
|The American Journal of Medicine|1980|2.4k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k